146 related articles for article (PubMed ID: 7372374)
1. Inhibition of effector cell functions in natural killer cell activity (NK) and antibody-dependent cellular cytotoxicity (ADCC) in mice by normal and cancer sera.
Nair PN; Fernandes G; Onoe K; Day NK; Good RA
Int J Cancer; 1980 May; 25(5):667-77. PubMed ID: 7372374
[No Abstract] [Full Text] [Related]
2. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors.
Rivera LM; Lopez DM
Anticancer Res; 1993; 13(1):177-84. PubMed ID: 8476211
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of natural killer activity and antibody-dependent cellular cytotoxicity in spleen cells of tumor bearing mice.
Ono M; Tanaka N; Orita K
Acta Med Okayama; 1983 Aug; 37(4):367-76. PubMed ID: 6605026
[TBL] [Abstract][Full Text] [Related]
4. The cell populations mediating natural killing-(NK) and antibody-dependent cell-mediated cytotoxicity are only partially identical.
Bardos P; Altman J; Guillou PJ; Carnaud C
Clin Exp Immunol; 1981 Mar; 43(3):534-9. PubMed ID: 7285391
[TBL] [Abstract][Full Text] [Related]
5. Decreased natural cytotoxicity in mice with high incidence of mammary adenocarcinoma.
Ames IH; Garcia AM; John PA; Litty CA; Farrell MA; Tomar RH
Clin Immunol Immunopathol; 1986 Feb; 38(2):265-73. PubMed ID: 3940744
[TBL] [Abstract][Full Text] [Related]
6. Systemic and in situ natural killer activity in transplanted and spontaneous mammary tumors in C3H/HeN mice.
Gerson JM; Tagliabue A; Herberman RB
J Reticuloendothel Soc; 1981 Jan; 29(1):15-21. PubMed ID: 7205815
[No Abstract] [Full Text] [Related]
7. Characterization of the effector cells mediating an "innocent bystander" cytotoxicity reaction induced by a syngeneic mammary adenocarcinoma in mice.
Paul RD; Padmanabhan R; Lopez DM
Cancer Res; 1984 Oct; 44(10):4480-6. PubMed ID: 6467207
[TBL] [Abstract][Full Text] [Related]
8. Tumour cells in metastatic deposits with altered sensitivity to natural killer cells.
Brooks CG; Flannery GR; Willmott N; Austin EB; Kenwrick S; Baldwin RW
Int J Cancer; 1981 Aug; 28(2):191-8. PubMed ID: 7319671
[TBL] [Abstract][Full Text] [Related]
9. Activation of NK activity and auto-reactive cytotoxicity after hepatectomy.
Ono M; Tanaka N; Orita K
Acta Med Okayama; 1984 Apr; 38(2):207-13. PubMed ID: 6610280
[TBL] [Abstract][Full Text] [Related]
10. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
Hager JC; Miller FR; Heppner GH
Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
[No Abstract] [Full Text] [Related]
11. Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities.
Kumagai K; Itoh K; Suzuki R; Hinuma S; Saitoh F
J Immunol; 1982 Jul; 129(1):388-94. PubMed ID: 6979572
[No Abstract] [Full Text] [Related]
12. Identity of effector cells participating in the reverse antibody-dependent cell-mediated cytotoxicity.
Saxena RK; Saxena QB; Adler WH
Immunology; 1982 Jun; 46(2):459-64. PubMed ID: 7084998
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
14. Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.
Ames IH; Gagne GM; Garcia AM; John PA; Scatorchia GM; Tomar RH; McAfee JG
Cancer Immunol Immunother; 1989; 29(2):93-100. PubMed ID: 2720709
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
Katz JD; Mitsuyasu R; Gottlieb MS; Lebow LT; Bonavida B
J Immunol; 1987 Jul; 139(1):55-60. PubMed ID: 3584988
[TBL] [Abstract][Full Text] [Related]
16. Corretation between immunosuppression to tumorigenesis. 1. Humoral immunosuppressing factor.
Hakim AA
Eur J Cancer (1965); 1978 Nov; 14(11):1249-60. PubMed ID: 738330
[No Abstract] [Full Text] [Related]
17. Emergence of a B lymphocyte population with ADCC effector function in mammary tumor bearing mice.
Padmanabhan RR; Paul RD; Watson GA; Lopez DM
J Leukoc Biol; 1988 Jun; 43(6):509-19. PubMed ID: 3259973
[TBL] [Abstract][Full Text] [Related]
18. Immunological responses to a murine mammary adenocarcinoma: cytolysis by armed monocyte and by antibody-dependent cellular cytotoxicity.
Yamamura Y
Oncology; 1980; 37(1):6-11. PubMed ID: 7350556
[TBL] [Abstract][Full Text] [Related]
19. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
20. Nuclear disintegration of target cells by killer B lymphocytes from tumor-bearing mice.
Lopez DM; Blomberg BB; Padmanabhan RR; Bourguignon LY
FASEB J; 1989 Jan; 3(1):37-43. PubMed ID: 2783411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
